<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191954</url>
  </required_header>
  <id_info>
    <org_study_id>9800</org_study_id>
    <nct_id>NCT04191954</nct_id>
  </id_info>
  <brief_title>Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)</brief_title>
  <official_title>Fasudil Eye Drop in Retinopathy Of Prematurity, Retinal Vascularization Induction and Disease Progression Inhibition, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible eyes are randomly assigned into two groups. Group A receive Fasudil eye drops
      (concentration 0.5 percent) twice daily. Group B, receive artificial tears drop with the same
      frequency. Retinal specialists who are expert in Retinopathy Of Prematurity field will
      perform fundus examination regularly. The examiners are blind. The progression of normal
      retinal vascularization and need to treatment will be documented and compared between the two
      study groups. The topical eye drops are used until the retinal vascularization are complete
      (45 week after LMP) or the patient needs to be treated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stimulation of normal retinal vascularization and disease progression inhibition</measure>
    <time_frame>3 months</time_frame>
    <description>Fundoscopy and examiner judgment which will be documented by retinal camera</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any adverse event</measure>
    <time_frame>3 months</time_frame>
    <description>Neonatologist and ophthalmologist examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Fasudil eye drops (concentration 0.5 percent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>receive artificial tears drop with the same frequency</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasudil eye drops (concentration 0.5 percent)</intervention_name>
    <description>receive Fasudil eye drops (concentration 0.5 percent) twice daily</description>
    <arm_group_label>Fasudil eye drops (concentration 0.5 percent)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>receive artificial tears drop</intervention_name>
    <description>receive artificial tears drop with the same frequency</description>
    <arm_group_label>receive artificial tears drop with the same frequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants who are candidate for retinopathy of prematurity (ROP) screening
             with ROP Type 2

        Exclusion Criteria:

          -  Serious systemic problems

          -  Other ocular problems Except ROP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alireza Ramezani, MD</last_name>
    <phone>009822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali reza Ramezani, MD</last_name>
      <phone>009822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasudil</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

